Publications by authors named "Dellon E"
Introduction: We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilic esophagitis (EoE) compared with other approved indications.
Methods: Results for the phase 3 LIBERTY EoE TREET study coprimary endpoints (proportion of patients achieving a peak intraepithelial eosinophil count of ≤6 eosinophils per high-power field and absolute change from baseline in Dysphagia Symptom Questionnaire total score) were pooled in exposure-response analyses.
Results: A steep initial relationship then plateau was observed between higher dupilumab steady-state trough concentrations and decreased eosinophilic infiltration at week 24, whereas a graded exposure-response relationship was observed for symptomatic improvement at week 24.
Purpose: Eosinophilic esophagitis (EoE), a chronic immune-mediated progressive disease, causes dysphagia, food impaction, abdominal pain, vomiting, and heartburn. EoE requires long-term monitoring and can affect quality of life owing to its symptoms and associated emotional and social burden. This study aimed to understand patients' experiences with EoE.
View Article and Find Full Text PDFACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis.
Am J Gastroenterol
January 2025
Article Synopsis
- Eosinophilic esophagitis (EoE) is a chronic immune disease characterized by symptoms of esophageal dysfunction and an eosinophil-dominated infiltration in the esophagus.
- The incidence of EoE is rising, requiring attention in various medical settings, leading to updated guidelines that focus on improved diagnosis and treatment strategies.
- Recommended treatments include proton pump inhibitors, topical steroids, dietary elimination, and esophageal dilation, with an emphasis on monitoring patients for treatment response and managing both inflammatory and structural aspects of the disease.
Background: Relapse after corticosteroid withdrawal in eosinophilic esophagitis is not well understood.
Objectives: Budesonide oral suspension (BOS) 2.0 mg twice daily (b.
Background: Enhancing family readiness for the healthcare transition (HCT) to adult-focused care can help adolescents and young adults (AYA) thrive in adulthood. We aimed to explore modifiable and non-modifiable individual, family, and healthcare factors associated with HCT readiness of AYA among families of AYA with cystic fibrosis (CF) during COVID-19.
Methods: A multi-site, cross-sectional design was used and an online survey was deployed among families and their AYA from three US pediatric CF centers.
Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).
Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.
High prevalence of eosinophilic gastrointestinal disorders in patients with atopic disease.
Ann Allergy Asthma Immunol
December 2024
Even as many outcomes for people living with cystic fibrosis (PLwCF) improve, individuals still experience extensive symptom burdens. From birth, many PLwCF experience both pain as a symptom of their CF disease and procedural pain, posing detriments to health, functioning, and quality of life. Despite its prevalence and impact, there is no CF-specific guidance for the assessment and management of pain.
View Article and Find Full Text PDFBackground: Predicting fibrostenotic complications prior to endoscopy in eosinophilic esophagitis (EoE) is challenging and esophageal strictures and narrowing are commonly missed on endoscopy.
Aim: To develop and validate a score to predict fibrostenosis in EoE patients prior to endoscopy.
Methods: We leveraged a large database of newly diagnosed EoE patients.
Article Synopsis
- The study investigates how previous esophageal dilation affects the effectiveness of swallowed corticosteroids in patients with eosinophilic esophagitis (EoE), particularly focusing on the responses to treatment.
- A post hoc analysis of a phase 3 study on budesonide oral suspension revealed that while histological responses were similar among patients regardless of dilation history, those with a history of dilation had lower dysphagia symptom response rates.
- The findings suggest that a history of esophageal dilation might complicate the relationship between histological results and dysphagia symptom or endoscopic efficacy outcomes in EoE treatment.
Background: While inflammation is implicated in the development of numerous cancers, whether eosinophilic oesophagitis (EoE) increases the risk of oesophageal cancer (OCa) remains understudied.
Aim: To assess whether adults with EoE were more likely to have subsequent OCa diagnosis.
Methods: This case-control study used data from the MarketScan commercial claims database.
Introduction: We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilic esophagitis (EoE) compared with other approved indications.
Methods: Results for the phase 3 LIBERTY EoE TREET study co-primary endpoints (proportion of patients achieving a peak intraepithelial eosinophil count of ≤6 eosinophils per high-power field and absolute change from baseline in Dysphagia Symptom Questionnaire total score) were pooled in exposure-response analyses.
Results: A steep initial relationship then plateau was observed between higher dupilumab steady state trough concentrations (Ctrough) and decreased eosinophilic infiltration at Week 24, while a graded exposure-response relationship was observed for symptomatic improvement at Week 24.
Article Synopsis
- * A study of 289 adults showed that 58% had esophageal motility disorders, with various types identified, despite normal barium swallow results in half of these cases.
- * Specific rheumatic conditions affected the likelihood of esophageal dysmotility, with lower rates in those with psoriatic arthritis and varying odds for rheumatoid arthritis and scleroderma.
Daily or Twice Daily Treatment with Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis.
Clin Gastroenterol Hepatol
November 2024
Background & Aims: Few data compare topical corticosteroid (tCS) dosing regimens and outcomes. We aimed to compare treatment outcomes in patients with eosinophilic esophagitis (EoE) by once or twice daily dosing regimens.
Methods: We conducted a retrospective cohort study using the UNC EoE Clinicopathologic Database of newly diagnosed patients with EoE treated with a tCS who had a follow-up endoscopy with biopsy.
Background: High placebo responses have limited drug development in eosinophilic oesophagitis. The optimal configuration of trial outcomes is uncertain.
Aims: To inform more efficient future trial designs, to characterise clinical, endoscopic and histologic placebo responses in eosinophilic oesophagitis randomised controlled trials (RCTs).
Prevalence and Costs of Eosinophilic Esophagitis in the United States.
Clin Gastroenterol Hepatol
February 2025
Background & Aims: Eosinophilic esophagitis (EoE) has been continually increasing in prevalence, but current estimates are lacking. We aimed to determine updated estimates of the prevalence and medical costs associated with EoE in the United States (U.S.
View Article and Find Full Text PDFIntroduction: Little is known about how patients make decisions about and prioritize therapies and disease management in eosinophilic esophagitis (EoE). We aimed to systematically identify and characterize patient perspectives and attitudes that influence decision making for EoE management.
Methods: To understand the diverse attitudes and values of patients with EoE, we designed a study using the Q-method.
Article Synopsis
- - Eosinophilic esophagitis (EoE) is a chronic inflammatory condition that affects eating and quality of life, with existing treatments not fully controlling symptoms for about one-third of patients.
- - A phase 2 study of cendakimab, an anti-IL-13 monoclonal antibody, showed promise in reducing inflammation in EoE patients, leading to a phase 3 study aimed at further evaluating its effectiveness and safety.
- - The phase 3 study will enroll 399 participants to test different dosing regimens of cendakimab against a placebo, focusing on symptoms like difficulty swallowing and histological improvements in eosinophil counts over 48 weeks.
Goals: To determine long-term efficacy and safety of tCS for treatment of EoE.
Background: Maintenance therapy with topical corticosteroids (tCS) is recommended for eosinophilic esophagitis (EoE), but data for long-term use are still needed.
Study: This retrospective cohort study assessed newly diagnosed patients with EoE who were treated with a tCS and had a follow-up endoscopy with biopsy after at least 5 years.
Article Synopsis
- Cannabis use is rising among people for both recreational and medical reasons, but there isn't much research on its effects in eosinophilic esophagitis (EoE).
- A study involved 983 newly diagnosed EoE patients, with 80 reporting cannabis use, mainly through inhalation and daily consumption.
- Findings indicated that cannabis users had milder initial symptoms but showed worse inflammatory responses after treatment compared to non-users, suggesting that cannabis may negatively affect EoE management.
Introduction: We aimed to estimate health state utility in eosinophilic esophagitis (EoE) by histologic activity and assess association with disease parameters.
Methods: In this cross-sectional study, we measured health state utility by time trade-off and assessed symptoms with the EoE Symptom Activity Index.
Results: In 51 adults with EoE, the mean utility was 0.
Background: Question prompt lists (QPLs) are structured sets of disease-specific questions intended to encourage question-asking by patients and enhance patient-physician communication. To date, an EoE-specific QPL has not been developed for EoE patients.
Aim: To develop a preliminary QPL specific to adults with EoE by incorporating input from international esophageal experts.